The US Food and Drug Administration (FDA) has granted 510(k) clearance to Seventh Sense Biosystems' (7SBio) new push-button blood collection device TAP.

The new device is claimed to provide a virtually painless, simple and fast blood collection process and eliminates the need for insertion of a long needle into a vein or lancet to a fingertip.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TAP can be placed on the upper arm and blood collection starts with a simple press of a button and takes about 2-3 minutes to be complete.

"TAP has the potential to transform blood collection from an inconvenient, stressful, and painful experience to one people can do themselves anywhere."

7SBio chief executive officer Howard Weisman said: "No one likes getting blood drawn, but blood is the single-most important source of medical information in healthcare today, with about 90% of all diagnostic information coming from blood and its components.

"TAP has the potential to transform blood collection from an inconvenient, stressful, and painful experience to one people can do themselves anywhere, making health monitoring much easier for both healthcare professionals and patients."

The current clearance allows the use of the device to collect capillary blood for hemoglobin A1c (HbA1c) testing to monitor blood sugar levels in diabetic or pre-diabetic patients.

It is expecyed that TAP can facilitate efficient blood collection in reference labs, hospitals, retail pharmacies, doctors' offices, wellness screenings, molecular diagnostics testing, athlete monitoring and clinical trials.

7SBio is currently working with the FDA to expand TAP's clearance for use in additional tests.

The firm also intends to develop and commercialise different versions of the device that would allow users to collect blood anywhere and anytime.